🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, escalating drug resistance and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone represents a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

Based on results published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses a dual-drug approach. The research involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians treating patients have expressed positive views. Access to a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is considered vital to lessen the impact of the disease for patients and to prevent the spread of extremely resistant gonorrhoea around the world.